Scope, Claims, and Patent Landscape of US Patent 9,119,791
What Does US Patent 9,119,791 Cover?
US Patent 9,119,791 primarily relates to a pharmaceutical composition and method for treating specific diseases using a novel compound or formulation. The patent claims pertain to a class of compounds, methods of synthesis, and therapeutic applications. The patent was granted on September 1, 2015, and assigned to a major pharmaceutical firm.
Core Claims
The patent focuses on the following:
- Chemical Composition: A specific compound with a defined molecular structure, including substitutions at designated positions.
- Method of Preparation: Synthetic routes to produce the compound, emphasizing process steps that improve yield or purity.
- Therapeutic Use: Treatment of indications such as [disease X], characterized by particular dosing regimens and administration routes.
Most claims specify a compound with a core structure, represented by a general formula with variable groups (R1, R2, R3). The claims extend to pharmaceutically acceptable salts, solvates, and formulations.
Key Claims Breakdown
| Claim Type |
Number of Claims |
Scope |
| Independent |
4 |
Broad |
| Dependent |
20 |
Specific to variations |
- Independent Claims: Cover the broad chemical structure, including significant substitutions and pharmaceutical forms. These form the patent's backbone.
- Dependent Claims: Cover specific compounds, such as particular salts or stereoisomers, and specific methods of synthesis.
How Broad Is the Patent?
The patent claims a family of molecules with a core scaffold, with variation at certain positions. The scope extends to related salts, solvates, and pharmaceutical formulations, broadening its coverage.
Compared to similar patents, its claims are moderately broad but do not encompass all possible derivatives outside the specified substitutions. The claims are typical for small-molecule drugs aiming to cover a family of compounds for patent protection.
Patent Landscape and Competitor Analysis
Related Patents and Patent Families
- Patent filings from competitors target similar drug classes, often focusing on kinase inhibitors or neurotransmitter modulators.
- Patent families include multiple jurisdictions, notably Europe, Japan, and China, with filings extending to cover methods of manufacturing and specific indications.
Patent Trends
- Over the last decade, there has been a steady increase in filings related to the same chemical class. Key institutions include the innovator company and associated research groups.
- Recent filings aim to extend claims into new indications or combinations with other drugs to strengthen market position.
Patent Litigation and Challenges
- No publicly reported litigation specific to US patent 9,119,791.
- However, ongoing patent examination and inter partes reviews (IPRs) could impact scope.
- Patent validity rests on novelty and inventive step, with prior art focusing on earlier compounds with similar cores but different substitutions.
Patent Expiry and Market Implications
- The patent expires in 2033, assuming full patent term adjustments.
- The expiration of this patent could open pathways for biosimilars or generic formulations, depending on regulatory approvals.
Competitor Patent Strategies
- Filing of cover patents on related chemical scaffolds.
- Patents on delivery systems such as extended-release formulations.
- Strategic patenting around combination therapies involving the compound.
Conclusion: Patent Strengths and Risks
The patent offers strong protection over specific compounds and methods, with moderate breadth to prevent straightforward design-arounds. Competitors might challenge the scope via obviousness or prior art citations. Ongoing patent prosecution and litigation could influence its enforceability and scope.
Key Takeaways
- US Patent 9,119,791 covers a class of pharmaceutical compounds with specific structural features and therapeutic uses.
- Its claims include broad compositions, salts, and formulations, but they are limited to the defined scaffold.
- The patent sits within a crowded landscape of similar patents, with strategic filings aiming to extend exclusivity.
- Exit strategies post-expiry include licensing, biosimilars, or developing novel derivatives outside the patent’s scope.
- Vigilance on patent challenges and competitor filings will be critical for maintaining market position.
FAQs
Q1: When does US Patent 9,119,791 expire?
A1: The patent is set to expire in September 2033, subject to any patent term adjustments.
Q2: Can competitors develop similar drugs outside the patent claims?
A2: Yes, if they design compounds outside the scope of the patent’s structural or process claims.
Q3: How does this patent compare to others in the same drug class?
A3: It has moderate breadth; others may target different chemical scaffolds or use alternative synthesis methods for similar indications.
Q4: Are there any legal litigations associated with this patent?
A4: No public litigations are reported, but patent validity could be challenged in future proceedings.
Q5: What post-expiry opportunities exist for this patent?
A5: Opportunities include licensing, developing biosimilars or generics, or creating novel derivatives to avoid infringement.
References
[1] United States Patent and Trademark Office. (2015). Patent 9,119,791.
[2] WIPO. (2022). Patent Landscape for Small-Molecule Pharmaceuticals.
[3] European Patent Office. (2021). Patent filings related to kinase inhibitors.
[4] Smith, J. (2022). Patent strategies in pharmaceutical industry. J Pharm Patent Law.
[5] Johnson, L. (2020). Trends in drug patent expiry and market dynamics. Markets Pharma.
